Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a

newsfileJun 27 12:29 ET

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 P.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a

newsfileJun 25 07:27 ET

Cardiol Therapeutics Releases Phase II Data Showing CardiolRx Reduces Pericarditis Pain and Inflammation | TSX:CRDL, NASDAQ:CRDL

Proactive InvestorsJun 13 08:08 ET

Cardiol Therapeutics Announces Positive Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx also shown to reduce inflammation in patients with elevated CRP89% of patients have

newsfileJun 13 07:58 ET

Sector Spotlight: Orphan Drug Developers With Significant Upside

Stockhouse Jun 3 07:00 ET

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 23 11:48 ET